

For immediate release 7.00am: 18 May 2017

HVIVO PLC
 (“hVIVO” or the “Company”)

Award of Deferred Bonus Share Options

hVIVO plc (AIM: HVO), a specialty biopharma company with clinical testing capabilities, announces that on 17 May 2017 it awarded the following options over ordinary shares of 5.0 pence each in the Company to persons discharging managerial responsibilities (“PDMR”):

PDMR	Total no. of shares under award	Type of awards
Kym Denny	32,813	Deferred Bonus Award
Graham Yeatman	26,250	Deferred Bonus Award

The deferred bonus share options will normally vest on the second anniversary of date of grant (17 May 2019), subject to continued employment but no other performance condition. The deferred bonus awards represent 50% of 2016 bonus awarded by the Remuneration Committee, with the other 50% paid as cash.

The exercise price payable per share is the nominal price of a share (currently 5 pence). Vested options will be able to be exercised up to the tenth anniversary of date of grant.

Details of the full notifications received by the Company are set out below:

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Kym Denny and Graham Yeatman
2	Reason for Notification	
a)	Position/status	Chief Executive Officer and Chief Financial & Business Officer
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	hVIVO PLC
b)	Legal Entity Identifier	2138003PFXHA22YPN676
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument	Ordinary shares of 5 pence each
	Identification code	GB00B6ZM0X53
b)	Nature of the transaction	Grant of deferred bonus share options as follows: The deferred bonus share options will normally vest on the second anniversary of date of grant (17 May 2019), subject to continued employment but no other performance condition. The exercise price payable per share is the nominal price of a share (currently 5 pence). Vested options will be able to be exercised up to the tenth anniversary of date of grant.

c)	Currency	GBP		
d)	Price(s) and volume(s)	Director	Price (p)	Volume
		Kym Denny	5.0	32,813
		Graham Yeatman	5.0	26,250
e)	Aggregated information - Aggregated volume - Price	59,063 shares 5.0 pence		
f)	Date of the transaction	17 May 2017		
g)	Place of the transaction	Outside a trading venue		

For further information please contact:

hVIVO plc

+44 207 756 1300

Kym Denny (Chief Executive Officer)

Graham Yeatman (Chief Financial & Business Officer)

Numis Securities Limited

+44 207 260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black / Michael Burke (Corporate Broking)

FTI Consulting

Simon Conway / Victoria Foster Mitchell (UK)

+44 203 727 1000

John Capodanno / Evan Smith (US)

+1 212 850 5705

Notes to Editors:

hVIVO plc (“hVIVO”), a specialty biopharma company with discovery and clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 45 clinical studies, inoculated over 2000 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.